
Joel Pekow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4689274/publications.pdf Version: 2024-02-01



LOFI DEKOW

#	Article	IF	CITATIONS
1	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease. Intestinal Research, 2022, 20, 303-312.	2.6	7
2	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. Intestinal Research, 2022, 20, 240-250.	2.6	10
3	Editorial: time to modify practice and use the modified Rutgeert's score. Alimentary Pharmacology and Therapeutics, 2022, 55, 754-755.	3.7	0
4	Editorial: response to tofacitinib is associated with high rates of longâ€ŧerm treatment persistence. Alimentary Pharmacology and Therapeutics, 2022, 55, 1222-1223.	3.7	0
5	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 104-110.	4.4	60
6	Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nature Immunology, 2021, 22, 471-484.	14.5	39
7	Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics, 2021, 16, 1317-1334.	2.7	10
8	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. Crohn's & Colitis 360, 2020, 2, otaa039.	1.1	8
9	A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nature Communications, 2020, 11, 6161.	12.8	76
10	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1365-1372.	3.7	8
11	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Reply Letter to Elia et al Inflammatory Bowel Diseases, 2020, 26, e94-e94.	1.9	0
12	Linear and circular CDKN2B-AS1 expression is associated with Inflammatory Bowel Disease and participates in intestinal barrier formation. Life Sciences, 2019, 231, 116571.	4.3	33
13	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonistâ€maintained clinical remission. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2090-2095.	2.8	6
14	Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer. Cancer Prevention Research, 2019, 12, 433-448.	1.5	4
15	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointestinal Endoscopy, 2019, 90, 269-275.	1.0	36
16	Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2019, 64, 1938-1944.	2.3	23
17	Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Digestive Diseases and Sciences, 2019, 64, 1945-1951.	2.3	80
18	IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. Journal of Crohn's and Colitis, 2019, 13, 884-893.	1.3	15

Joel Pekow

#	Article	IF	CITATIONS
19	Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation inÂtheÂProximal Colon. Clinical Gastroenterology and Hepatology, 2018, 16, 68-74.	4.4	45
20	Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis. Oncotarget, 2018, 9, 20709-20720.	1.8	7
21	Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Surgical Infections, 2018, 19, 785-791.	1.4	6
22	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2634-2640.	1.9	20
23	Identification of novel mRNAs and IncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2018, 315, G722-G733.	3.4	18
24	A comparison of the risk of postoperative recurrence between Africanâ€American and Caucasian patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 933-940.	3.7	12
25	miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflammatory Bowel Diseases, 2017, 23, 1328-1337.	1.9	22
26	miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clinical Cancer Research, 2017, 23, 5281-5291.	7.0	73
27	Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Diseases, 2017, 23, 152-157.	1.9	110
28	ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer. Clinical Cancer Research, 2017, 23, 549-561.	7.0	40
29	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS ONE, 2017, 12, e0182900.	2.5	39
30	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis,. American Journal of Clinical Nutrition, 2016, 104, 113-120.	4.7	78
31	Northern Latitude but Not Season Is Associated with Increased Rates of Hospitalizations Related to Inflammatory Bowel Disease: Results of a Multi-Year Analysis of a National Cohort. PLoS ONE, 2016, 11, e0161523.	2.5	17
32	The emerging role of miRNAs in inflammatory bowel disease: a review. Therapeutic Advances in Gastroenterology, 2015, 8, 4-22.	3.2	136
33	Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. American Journal of Physiology - Renal Physiology, 2015, 308, G179-G187.	3.4	39
34	Is RXRα Crucially Involved in Intestinal Inflammation?. Digestive Diseases and Sciences, 2014, 59, 702-703.	2.3	2
35	The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer. Clinical Cancer Research, 2014, 20, 5848-5859.	7.0	40
36	Clinical Presentation and Disease Course of Inflammatory Bowel Disease Differs by Race in a Large Tertiary Care Hospital. Digestive Diseases and Sciences, 2014, 59, 2228-2235.	2.3	34

Joel Pekow

#	Article	IF	CITATIONS
37	Gene Signature Distinguishes Patients with Chronic Ulcerative Colitis Harboring Remote Neoplastic Lesions. Inflammatory Bowel Diseases, 2013, 19, 461-470.	1.9	39
38	Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. Journal of Clinical Investigation, 2013, 123, 3983-3996.	8.2	270
39	Association Between Higher Predicted Serum Vitamin D Levels and Reduced Incidence of Inflammatory Bowel Diseases. Gastroenterology, 2012, 143, e28.	1.3	1
40	EGFR Signals Downregulate Tumor Suppressors miR-143 and miR-145 in Western Diet–Promoted Murine Colon Cancer: Role of G1 Regulators. Molecular Cancer Research, 2011, 9, 960-975.	3.4	114